Menstrual Migraine and Hormonal Triggers

Menstrual Migraine and Hormonal Triggers — scientific infographic poster

Table of Contents

  1. Why Hormones Drive Migraine
  2. The Estrogen-Withdrawal Hypothesis
  3. Pure Menstrual Migraine vs. Menstrually-Related Migraine
  4. The Headache Diary — Three Cycles to a Diagnosis
  5. Short-Term ("Mini") Prevention Around Your Period
  6. Continuous-Dose Contraceptives — Suppressing the Cycle
  7. The Aura Problem and Stroke Risk
  8. Progestin-Only Options for Aura Patients
  9. Transdermal Estradiol — MacGregor's Add-Back Strategy
  10. Perimenopause — When It Gets Worse Before It Gets Better
  11. Hormone Replacement Therapy Decisions — Transdermal, Body-Identical, Cyclic vs. Continuous
  12. Surgical Menopause and Oophorectomy
  13. Pregnancy, Postpartum, and Breastfeeding
  14. Endometriosis, Adenomyosis, Polycystic Ovary Syndrome, Thyroid, and PMDD
  15. The Steps Described for Menstrual Migraine, in Order
  16. Key Research Papers
  17. Connections
  18. Featured Videos

Why Hormones Drive Migraine

Before puberty, boys and girls get migraine at roughly the same rate. After puberty, women outnumber men about three to one. The gap opens the year estrogen begins cycling and narrows again after menopause. That single epidemiological fact tells you almost everything you need to know: migraine in women is, to a large extent, a hormonally-driven disease.

About 60% of women with migraine notice attacks clustered around their period. For roughly 10–14%, every single attack is tied to the menstrual window. Menstrual attacks tend to be longer, more severe, less responsive to the usual acute medications, and more likely to recur within 24 hours. They are not in your head, not imagined, and not a character flaw — they are a predictable neurobiological response to a hormone that is falling out from under your brain once a month.

The good news: because menstrual migraine is predictable, it is one of the few migraine subtypes where you can schedule prevention. You know the enemy's arrival date. That changes the strategy.

The Estrogen-Withdrawal Hypothesis

The dominant explanation for why periods trigger migraine is the estrogen-withdrawal hypothesis, articulated most clearly by British headache specialist Anne MacGregor. The idea is straightforward. During the late luteal phase (the week before your period), estrogen levels are relatively high. Two to three days before bleeding begins, estrogen plummets. That steep drop — not the low level itself — is what destabilizes the trigeminovascular system and lowers the migraine threshold.

Evidence supporting this model:

The estrogen-withdrawal model does not explain every menstrual attack — prostaglandin surges from the endometrium, serotonin fluctuations, and CGRP sensitivity all play roles — but it explains enough to drive real treatment decisions.

Pure Menstrual Migraine vs. Menstrually-Related Migraine

The International Classification of Headache Disorders, third edition (ICHD-3), splits menstrual migraine into two categories that sound similar but matter clinically.

Pure menstrual migraine without aura (PMM) — ICHD-3 code A1.1.1. Attacks occur only during the perimenstrual window (days -2 to +3) in at least two of every three cycles, and at no other time of the month. Roughly 10–14% of women with migraine meet this definition. PMM is the cleanest target: if your brain only fires during that five-day window, you only need prevention for five days a month.

Menstrually-related migraine without aura (MRM) — ICHD-3 code A1.1.2. Attacks occur reliably during the perimenstrual window and at other times throughout the cycle. This is far more common — about 35–50% of female migraine patients. Mini-prevention can still help, but you usually need a background preventive too.

The distinction matters because PMM often responds beautifully to short-term ("mini") prevention alone, while MRM usually needs a layered approach: daily preventive plus targeted perimenstrual coverage.

Both definitions specifically exclude aura. Menstrual attacks with aura exist but are less common and sit in a different risk category because of the stroke and contraceptive implications discussed below.

The Headache Diary — Three Cycles to a Diagnosis

Before your doctor can prescribe mini-prevention, you both need to know whether your migraines are actually menstrually linked. Memory is unreliable. A three-month headache diary is.

Track, every day:

Free options include headache-diary apps or a plain paper calendar. After three complete cycles, laying the headache days over the cycle days shows the pattern: a clear cluster in the day -2 to +3 window is the menstrual pattern described above. A written record of this kind also gives a clinician the pattern at a glance.

Short-Term ("Mini") Prevention Around Your Period

Mini-prevention means starting a medication two days before your expected period and continuing for five to seven days through the high-risk window. You take nothing the rest of the month. In Silberstein's 2004 trial of 546 women, menstrual migraine occurred during the 6-day window in 67% of cycles on placebo, 52% on frovatriptan 2.5 mg once daily and 41% on 2.5 mg twice daily; both doses also shortened and softened the attacks that did occur, and side effects were similar to placebo. The approach keeps cumulative drug exposure low.

The evidence-based regimens:

Mini-prevention works only if your cycles are reasonably predictable (within two or three days). If your cycles are irregular, you will miss the window half the time. In that case, cycle suppression (see below) is usually a better approach.

A practical tactic: keep a rescue acute medication (a second triptan, a gepant like ubrogepant or rimegepant, or a ditan like lasmiditan) on hand for breakthrough attacks that punch through mini-prevention. See the triptans and gepants article for acute-treatment choices.

A 2024 meta-analysis of 26 randomized trials in menstrual migraine (Khoo and colleagues) found that triptans, with or without other painkillers, beat placebo for both treating and preventing menstrual attacks. Sumatriptan and lasmiditan gave the best pain relief at 2 hours and 24 hours. For prevention, frovatriptan was the most effective of the triptans at stopping headaches from coming back, while the CGRP antibodies erenumab and galcanezumab cut headache days per month more than the triptans did.

Continuous-Dose Contraceptives — Suppressing the Cycle

If the estrogen-withdrawal hypothesis is correct, the cleanest solution is to stop the withdrawal from happening. Continuous-dose combined oral contraceptives (COCs) do exactly that: you skip the placebo/pill-free week and take active pills every day, eliminating the monthly estrogen drop.

Options that work:

Calhoun's 2017 review of hormonal contraception and migraine with aura focused on estrogen dose: it reported that studies consistently show no increase in stroke risk with today's very low-dose combined pills containing 20–25 mcg ethinyl estradiol, and that continuous ultra-low-dose formulations (10–15 mcg) may even reduce how often aura occurs. The review also notes that current guidelines still restrict these pills in migraine with aura. Continuous dosing prevents the monthly estrogen cliff; cyclic dosing recreates it every month.

Critical caveat: under current guidelines, combined (estrogen-containing) contraceptives are used only in women with migraine without aura. The next section explains the aura restriction.

The Aura Problem and Stroke Risk

Migraine with aura roughly doubles the baseline ischemic stroke risk in young women. Combined oral contraceptives, by raising estrogen-mediated clotting factors, add their own modest stroke risk. When you stack them, the combined risk rises enough that the World Health Organization, the American College of Obstetricians and Gynecologists, and the U.S. Centers for Disease Control and Prevention (CDC) all classify combined hormonal contraceptives as contraindicated (category 4) in women with migraine with aura. Smoking on top of this is the tripwire that turns a small absolute risk into a meaningful one.

What this means in practice:

See the aura article for how to identify whether what you experience meets the diagnostic definition.

Progestin-Only Options for Aura Patients

Progestin-only contraception carries no measurable added stroke risk and is safe in migraine with aura. Several forms exist, and any of them — when they successfully suppress ovulation and therefore suppress the cyclic estrogen drop — can reduce menstrual migraine frequency.

Progestin-only methods do not have the same clean dose-response relationship with migraine that combined pills do, so results vary from woman to woman. Some women get dramatic relief; a smaller fraction get worse (usually because of irregular spotting that amounts to continuous mini-withdrawal events). Three to four months is the usual period allowed before a method is judged.

Transdermal Estradiol — MacGregor's Add-Back Strategy

For women with regular cycles and clear PMM who either cannot take combined contraceptives (because of aura) or who simply want to preserve their cycle, MacGregor developed an elegant alternative: leave the natural cycle alone, but plug the estrogen cliff with a short course of transdermal estradiol around the period.

The classic regimen:

Lower doses (50 or 75 mcg) have been trialed and appear less effective than 100 mcg, and even the 100 mcg dose has a mixed trial record (below). Gel formulations (1.5 mg estradiol gel daily during the window) are an alternative when patches irritate the skin or detach. This approach is not contraceptive — it does not prevent pregnancy — and it is not universally covered by U.S. insurance. It is the most physiologically targeted hormonal approach to PMM, but the trials below show it does not reliably work.

What the trials found. In MacGregor's own 2006 crossover trial (35 women analysed), estradiol gel applied from the tenth day after a home fertility monitor showed peak fertility until the second full day of bleeding cut migraine days by 22% while the gel was used, and those attacks were milder. But in the 5 days after the gel stopped, migraine rose by 40% compared with placebo: the estrogen drop was delayed, not avoided, and the benefit was offset. A 2011 Swedish crossover trial of a 100 mcg-per-day estradiol patch for two weeks around the period (27 women) found no difference from placebo in the number or severity of attacks, although both estradiol and placebo did better than before treatment. How to avoid the rebound (for example by using estradiol for longer) has not been worked out.

Perimenopause — When It Gets Worse Before It Gets Better

Many women assume menopause means migraine relief. Eventually, yes. But the four to ten years of perimenopause that precede the final period are often the worst migraine years of a woman's life, and nobody warns patients about it.

The physiology: during perimenopause, ovarian follicles become erratic. Estrogen does not gradually decline — it swings wildly, sometimes higher than normal, sometimes crashing. Every crash is an estrogen-withdrawal event, and crashes can happen multiple times per cycle rather than once. Progesterone production also falls unpredictably, which amplifies the swings. Cycles shorten, lengthen, skip entirely, then return with a vengeance.

Patterns patients commonly report:

Average age at menopause in the U.S. is 51. If your migraines are getting worse in your early-to-mid forties, perimenopause is almost certainly part of the picture. The workup is clinical — follicle-stimulating hormone (FSH) levels are unreliable during perimenopause because they fluctuate as much as estrogen does — but a pattern of worsening migraine plus hot flashes, sleep disruption, or cycle change is enough to act on.

Hormone Replacement Therapy Decisions — Transdermal, Body-Identical, Cyclic vs. Continuous

Hormone replacement therapy (HRT, now often called MHT — menopausal hormone therapy) can stabilize perimenopausal and postmenopausal migraine, but the form of hormone replacement therapy matters enormously for headache outcomes.

Surgical Menopause and Oophorectomy

Removal of both ovaries — bilateral oophorectomy — is a hormonal catastrophe for most migraine patients. Overnight, estrogen crashes from premenopausal levels to zero, with no taper. Migraine typically worsens dramatically in the weeks and months after surgery, and may not resettle for a year or more.

If you have migraine and are considering oophorectomy (for endometriosis, ovarian masses, cancer risk, or another indication), bring the topic up explicitly with your surgeon and headache specialist before the operation. Starting transdermal estradiol on the day of surgery and continuing it at least until the natural age of menopause (~51) blunts the crash and is usually appropriate even in women who would otherwise be ambivalent about hormone replacement therapy. Hysterectomy without oophorectomy does not cause this problem because the ovaries continue to function.

Pregnancy, Postpartum, and Breastfeeding

Pregnancy is, for most migraine patients, a reprieve. The data:

Acute medications during pregnancy: acetaminophen is first-line. Metoclopramide (antiemetic with migraine-aborting properties) is generally considered safe. In 2020 the U.S. Food and Drug Administration (FDA) warned that nonsteroidal anti-inflammatory drugs (NSAIDs) used at about 20 weeks of pregnancy or later may cause rare but serious kidney problems in the unborn baby, leading to low amniotic fluid; the ductus-arteriosus concern is added in the third trimester. Triptans — particularly sumatriptan, which has the largest registry data — are not formally approved but are widely used when benefits outweigh risks; large observational cohorts have not shown clear harm. Ergotamine and dihydroergotamine (DHE) are contraindicated. Gepants and CGRP monoclonal antibodies lack pregnancy data and are generally stopped before conception.

Breastfeeding-safe acute options: acetaminophen, ibuprofen (preferred nonsteroidal anti-inflammatory drug (NSAID) while nursing because of its short half-life and low milk transfer), sumatriptan (minimal transfer, considered compatible), eletriptan (even lower transfer). Aspirin is not on the nursing-compatible list because of Reye-syndrome concerns in the infant. The LactMed database (free, U.S. National Institutes of Health, NIH) is the authoritative source when a specific drug comes up.

Endometriosis, Adenomyosis, Polycystic Ovary Syndrome, Thyroid, and PMDD

Menstrual migraine rarely travels alone. The conditions that cluster with it share hormonal machinery, and treating one often helps the others.

The Steps Described for Menstrual Migraine, in Order

The list below gathers, in order, the steps the research and guidelines on this page describe. Which steps fit depends on cycle regularity, aura and life stage.

  1. Three-cycle headache diary. It confirms the pattern and whether aura is present.
  2. Basic labs commonly checked: complete blood count (CBC), ferritin (heavy periods can cause iron deficiency, which lowers the migraine threshold), thyroid-stimulating hormone + free T4, vitamin D, and sometimes thyroid antibodies.
  3. Magnesium glycinate 400–600 mg daily and riboflavin 400 mg daily are the amounts described for these supplements — both have randomized-trial evidence in general migraine prevention and a low side-effect profile. See the supplements article.
  4. Regular cycles and PMM: mini-prevention with frovatriptan 2.5 mg twice daily for 6 days starting day -2 (the regimen tested by Silberstein), or naproxen 550 mg twice daily as a non-hormonal alternative.
  5. Irregular cycles, or mini-prevention not working, and no aura: continuous-dose combined contraception.
  6. Aura present: progestin-only options (desogestrel, levonorgestrel intrauterine system) or MacGregor's transdermal estradiol add-back around menses, whose trial results are mixed.
  7. Perimenopause: transdermal hormone replacement therapy (body-identical progesterone, continuous rather than cyclic), with a CGRP preventive as an option for background control.
  8. Attacks still frequent despite the above: a daily background preventive — a CGRP monoclonal antibody, atogepant, topiramate, or a beta-blocker. See the CGRP and preventives article.
  9. Medication overuse. Under the International Classification of Headache Disorders (ICHD-3), regular use of triptans or of combination painkillers on 10 or more days a month for more than 3 months can cause medication-overuse headache — headache on 15 or more days a month that usually, but not always, settles once the overuse stops. See the medication-overuse article.

Menstrual migraine is not a character of your cycle you are stuck with. It is a specific, well-characterized neurobiological event with specific, well-characterized interventions. Most women who work through this list in order find a combination that cuts their attack frequency at least in half, often more.

Key Research Papers

  1. MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A. Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology. 2006;67(12):2154-2158. — doi:10.1212/01.wnl.0000233888.18228.19
  2. Silberstein SD, Elkind AH, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology. 2004;63(2):261-269. — doi:10.1212/01.wnl.0000134620.30129.d6
  3. Calhoun AH. Hormonal Contraceptives and Migraine With Aura-Is There Still a Risk? Headache. 2017;57(2):184-193. — PMID: 27774589
  4. Sacco S, Merki-Feld GS, Ægidius KL, et al. Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). J Headache Pain. 2017;18(1):108. — PMID: 29086160
  5. MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A. Prevention of menstrual attacks of migraine: a double-blind placebo-controlled crossover study. Neurology. 2006;67(12):2159-2163. — PMID: 17190936
  6. Almén-Christensson A, Hammar M, Lindh-Åstrand L, Landtblom AM, Brynhildsen J. Prevention of menstrual migraine with perimenstrual transdermal 17-β-estradiol: a randomized, placebo-controlled, double-blind crossover study. Fertil Steril. 2011;96(2):498-500.e1. — PMID: 21704313
  7. Khoo CC, Liu CC, Lu M, Huang YC, Weng HY. Acute and preventive treatment of menstrual migraine: a meta-analysis. J Headache Pain. 2024;25(1):143. — PMID: 39227797

PubMed Topic Searches

For further reading, the following PubMed topic searches return current peer-reviewed work on menstrual migraine and the hormonal interventions discussed above:

  1. PubMed: Menstrual migraine and estrogen withdrawal
  2. PubMed: Frovatriptan short-term prevention
  3. PubMed: Naproxen for menstrual migraine
  4. PubMed: Continuous-dose oral contraceptives and migraine
  5. PubMed: Migraine with aura, stroke risk, and oral contraceptives
  6. PubMed: Transdermal estradiol for menstrual migraine
  7. PubMed: Perimenopause and migraine
  8. PubMed: Hormone replacement therapy and migraine
  9. PubMed: Pregnancy, trimester effects, and migraine
  10. PubMed: Postpartum and breastfeeding-safe migraine treatment
  11. PubMed: Endometriosis and migraine comorbidity
  12. PubMed: PMDD, serotonin, and menstrual migraine

Back to Table of Contents

Connections

Back to Table of Contents